Neoadjuvant chemotherapy and interval cytoreductive surgery have gradually become one of the mainstream modes for treating advanced epithelial ovarian cancer

but there are still many problems in their clinical application which need to be considered. This article describes the value and controversies of the application of neoadjuvant chemotherapy in patients with advanced ovarian cancer

in order to arouse the attention and in-depth thinking of the majority of gynecological oncologists

and promote the rational application and clinical research of neoadjuvant chemotherapy.